2006
Systematic review: the lower gastrointestinal adverse effects of non‐steroidal anti‐inflammatory drugs
LAINE L, SMITH R, MIN K, CHEN C, DUBOIS RW. Systematic review: the lower gastrointestinal adverse effects of non‐steroidal anti‐inflammatory drugs. Alimentary Pharmacology & Therapeutics 2006, 24: 751-767. PMID: 16918879, DOI: 10.1111/j.1365-2036.2006.03043.x.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsLower gastrointestinal adverse effectsLower gastrointestinal injuryGastrointestinal adverse effectsAnti-inflammatory drugsGastrointestinal injuryGastrointestinal effectsClinical eventsAdverse effectsNon-selective non-steroidal anti-inflammatory drugsUpper gastrointestinal effectsHigh-quality trialsLower gastrointestinal tractEndoscopic studyGastrointestinal integrityGastrointestinal tractComputerized databaseCoxibsDisease StudyInjuryLower ratesTrialsDrugsCohortLess effect
1999
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J, Group F. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117: 776-783. PMID: 10500058, DOI: 10.1016/s0016-5085(99)70334-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDuodenal UlcerFemaleGastric MucosaGastroscopyHumansIbuprofenIntestinal MucosaIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesStomach UlcerSulfonesConceptsUlcer ratesGastroduodenal ulcersCOX-2 specific inhibitionSymptoms of osteoarthritisNonspecific COX inhibitorNormal gastrointestinal tractTreatment of patientsBaseline endoscopyGastroduodenal ulcerationPlacebo groupCumulative incidenceOsteoarthritis patientsGastroduodenal mucosaWeek 12COX inhibitorsMucosal integrityCOX-2Gastrointestinal tractInflammatory sitesProstaglandin productionDoses 2AbstractTextEffective doseUlcersPatients
1988
Effect of oral iron therapy on the upper gastrointestinal tract
Laine L, Bentley E, Chandrasoma P. Effect of oral iron therapy on the upper gastrointestinal tract. Digestive Diseases And Sciences 1988, 33: 172-177. PMID: 3257437, DOI: 10.1007/bf01535729.Peer-Reviewed Original ResearchConceptsOral iron therapyUpper gastrointestinal tractIron therapyGastrointestinal symptomsHemoccult testGastrointestinal tractHealthy volunteersFecal occult blood testingHemoccult-positive stoolsOccult blood testingOral ferrous sulfateFresh stool samplesPositive Hemoccult testUncertain clinical significanceDark stoolsHemoccult testingEndoscopic abnormalitiesOral ironSignificant nauseaUnderwent endoscopyEndoscopic findingsSubepithelial hemorrhageBlood testingStool samplesClinical significance
1987
Protein-Losing Enteropathy in Acquired Immunodeficiency Syndrome due to Intestinal Kaposi's Sarcoma
Laine L, Politoske EJ, Gill P. Protein-Losing Enteropathy in Acquired Immunodeficiency Syndrome due to Intestinal Kaposi's Sarcoma. JAMA Internal Medicine 1987, 147: 1174-1175. PMID: 3592885, DOI: 10.1001/archinte.1987.00370060170028.Peer-Reviewed Original ResearchConceptsProtein-losing enteropathyIntestinal Kaposi's sarcomaKaposi's sarcomaImmunodeficiency syndromeFecal alpha-1-antitrypsinAcquired Immunodeficiency SyndromeAlpha-1 antitrypsinAnkle edemaPleural effusionMarked elevationGastrointestinal tractSarcomaEnteropathyPatientsHypoalbuminemiaAIDSSyndromeEdemaEffusionTractAntitrypsinMonths